Diet, amyloid enhancing factor (AEF) and amyloidogenesis: An hypothesis

Amyloid

Volumn 6, Issue 2, 1999, Pages 107-113

  Cathcart, Edgar S ^a,b   Elliott Bryant, Rosemary ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA New England Healthcare System   (United States)

Author keywords

Amyloid enhancing factor; Diet; Proteoglycans

Indexed keywords

AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HIGH DENSITY LIPOPROTEIN; PRION PROTEIN; PROTEOGLYCAN;

AMYLOIDOSIS; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CHRONIC INFLAMMATION; CREUTZFELDT JAKOB DISEASE; DIET; HUMAN; HYPOTHESIS; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK FACTOR;

EID: 0032814721     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129909007310     Document Type: Article

References (75)

1. 1 Cohen AS (1967). Amyloidosis. New Engl J Med 277, 522-530
2. 2 Glenner GG (1980). Amyloid deposits and amyloidosis: the β-fibrilloses. N Engl J Med 302, 1283-1292
3. 3 Sipe JD (1992). Amyloidosis. Annu Rev Biochem 61, 947-975
4. 4 Hoffman JS and Benditt EP (1976). Changes in high-density lipoprotein content following endotoxin administration in the mouse. J Biol Chem 257, 10510-10517
5. 5 McAdam KPWJ and Sipe JD (1976). Murine model for human secondary amyloidosis. Genetic variability of the acute phase response to endotoxins and casein. J Exp Med 144, 1121-1127
6. 6 Tape C and Kisilevsky R (1990). Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1043, 295-300
7. 7 Yamada T, Liepnieks J, Benson MD and Kluve-Beckerman B (1996). Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol 157,901-907
8. 8 Lavie G, Zucker-Franklin D and Franklin EC (1978). Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med 148, 1020-1031
9. 9 Westermark GT, U Engstrom, P Westermark. 1992. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 182:27-33
10. 10 Elliott-Bryant R, Liang J-s, Sipe JD and Cathcart ES (1998). Catabolism of lipid-free recombinant apolipoprotein serum amyloid A by mouse macrophages in vitro results in removal of the amyloid fibril forming amino terminus. Scand J Immunol 48, 241-247
11. 11 Chronopoulos S, Laird DW and Ali-Khan Z (1994). Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: confocal and immunogold electron microscopic studies J Pathol 173, 361-369
12. 12 Guo JT, Aldrich CE, Mason WS and Pugh JC (1996). Characterization of serum amyloid A protein mRNA expression and secondary amyloidosis in the domestic duck. Proc Natl Acad Sci USA 93, 14548-14553
13. 13 Shirahama T and Cohen AS (1975). Intralysosomal formation of amyloid fibrils. Am J Pathol 81, 101-106
14. 14 Scott JE (1990). Proteoglycan-collagen interactions and subfibrillar structure in collagen fibrils. Implications in the development and ageing of connective tissues. J Anat 169, 23-25
15. 15 Scott JE (1992). Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in the tissues. FASEBJ 6, 2639-2645
16. 16 Snow AD and Kisilevsky R (1985). Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis: a histochemical study. Lab Invest 53, 37-44
17. 17 Stenstad T, Magnus JH and Husby G. (1994). Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 303, 663-670
18. 18 Linker A and Carney HC (1987). Presence and role of glycosaminoglycans in amyloidosis. Lab Invest 57, 297-305
19. 19 Lyon AW, Anastassiades T and Kisilevsky R (1993). In vitro analysis of murine sulfate metabolism and splenic glycosaminoglycans biosynthesis during acute inflammation and amyloidosis. J Rheumatol 20, 1108-1113
20. 20 Ailles L, Kisilevsky R and Young ID (1993). Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 69, 443-448
21. 21 Lindahl B and Lindahl U (1997). Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 272, 26091-26094
22. 22 McCubbin WD, Way CM, Narindrasorasuk S and Kisilevsky R (1988). Circular-dichroism studies on two serum amyloid proteins. J Biochem 256, 775-779
23. 23 Fraser PE, Nguyen JT, Chin DT and Kirschner DA (1992). Effects of sulfate ions on Alzheimer's β/A4 peptide assembly: implications for amyloid-fibril proteoglycan interactions. J Neurochem 1992, 59: 1531-1540
24. 24 Castillo GM, Ngo C, Cummings J, Wight TN and Snow AD (1997). Perlecan binds to the β-amyloid fibrils (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J Neurochem 69, 2452-2465
25. 25 Van Nostrand WE, Melchor JP and Ruffini L (1998). Pathologic amyloid β-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 70, 216-223
26. 26 Priola SA, Caughey B, Raymond GJ and Chesebro B (1994). Prion protein and the scrapie agent: in vitro studies in infected neuroblastoma cells. Infect Agents Dis 3, 54-58
27. 27 Kelly JW (1998). The environmental dependency of protein folding best explains prion and amyloid diseases. Proc Natl Acad Sci USA 95, 930-932
28. 28 Malle E, Steinmetz A and Raynes JG (1993). Serum amyloid A-an cute phase protein and lipoprotein. Atherosclerosis 102, 131-146
29. p) binds cholesterol and modulates cholesterol flux. J Lipid Res 36, 37-46
30. 30 Bausserman L, Herbert PN, Forte T, Klausner RD, MacAdam KPWJ, Osborne JC Jr. and Rosseneu M (1983). Interaction of serum amyloid A proteins with phospholipids J Biol Chem 258,10681-10688
31. 31 Miloy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C and Kelly JW (1996). Inhibiting transytheretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 93, 15051-15056
32. 32 Cohen AS and Cathcart ES (1972). Casein-induced experimental amyloidosis: I. Review of cellular and immunologic aspects. Methods Achieve Exp Pathol 6, 207-242
33. 33 Sipe JD, Carreras I, Gonnerman WA, Cathcart ES, de Beer MC and de Beer FC (1993). Characterization of the inbred CE/J mouse strain as amyloid resistant. Am J Pathol 143, 1480-1485
34. 34 de Beer MC, de Beer FC, McCubbin WD, Kay CM and Kindy MS (1993). Structural prerequisites for serum amyloid A formation. J Biol Chem 268, 20606-20612
35. 35 Yamamoto K and Migita S (1985). Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 82,2915-2918
36. 36 Gonnerman WA, Elliott-Bryant R, Carreras I, Sipe JD and Cathcart ES (1995). Linkage of protection against amyloid fibril formation in the mouse to a single autosomal dominant gene. J Exp Med 181, 2249-2252
37. 2 expressed by amyloid susceptible CBA/J mice. Biochim Biophys Acta 1394, 121-126
38. 38 Kirschner DA, Elliott-Bryant R, Szumowski KE, Gonnerman WA, Kindy MS, Sipe JD and Cathcart ES (1999). In vitro amyloid fibril formation by synthetic peptides corresponding to the amino terminus of apoSAA isoforms from amyloid-susceptible and amyloid-resistant mice. J Structural Biol In press
39. 39 Yonezu T, Tsunasawa S, Higuchi K, Kogishi K, Naiki H, Hanada K, Sakiyama F and Takeda T (1987). A molecular-pathologic approach to murine senile amyloidosis. Lab Invest 57, 65-70
40. 40 Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hoffman A and Smith PG. (1996). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925
41. 41 Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, Mackenzie JM and Will RG (1997). New variant Creutzfeldt disease: neurological features and diagnostic tests. Lancet 350, 903-907
42. 42 Maury CPJ, Nurmiaho-Lassila E-L and Rossi H (1994). Amyloid fibril formation in gelsolin-derived amyloidosis. Lab Invest 70, 558-564
43. 43 Jacobson DR and Bauxbaum JN (1991). Genetic aspects of amyloidosis. Adv Hum Genet 20, 69-118
44. 44 Wallace MR, Dwulet FE, Conneally PM and Benson MD (1986). Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 78, 6-12
45. 45 Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dolson CM, Bradford SE, Blake CC and Pepys MB (1997). Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793
46. 46 Perutz MF (1997). Amyloid fibrils. Mutations make enzyme polymerize. Nature 385, 773
47. 47 Williams RC, Cathcart ES, Calkins E, Fite GL, Rubio JB and Cohen AS (1965) Secondary amyloidosis in lepromatous leprosy: Possible relations of diet and environment. Ann Int Med 62, 1000-1007, 1965
48. 48 Cathcart ES, Leslie CA, Meydani SN and Hayes KC (1987). A fish oil diet retards experimental amyloidosis, modulates lymphocyte function and decreases macrophage arachidonate metabolism in mice. J. Immunol 139,1850-1854
49. 49 Cathcart ES, Gonnerman WA, Elliott-Bryant R, Hajri T and Hayes KC (1997). Dietary modulation of apolipoprotein serum amyloid A (apoSAA) metabolism and prevention of amyloidosis in aging C57BL/6J and SJL/J mice. J Nutr Biochem 16, 8-15
50. 50 Newberne PM and McConnel RG (1980). Dietary nutrients and contaminants in laboratory animal experimentation. J Environ Path Tox 4, 105-122
51. 51 Beyreuther K and Masters CL (1994). Catching the culprit prion. Nature 370, 419-420
52. 52 Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J, Doey LJ and Lantos P (1997). The same prion strain causes vCJD and BSE. Nature 389, 448-450
53. 53 Bruce ME, Will R.G., Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H and Bostock CJ (1997). Transmission to mice indicates that a 'new variant' CJD is caused by the BSE agent. Nature 389, 498-501
54. 54 Prusiner SB (1997). Prion diseases and the BSE crisis. Science 278, 245-251
55. 55 Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James T.L, Cohen FE and Prusiner SB (1997). Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Nat. Acad Sci USA 94, 10069-10074
56. 56 Chesebro B (1998). BSE and prions: uncertainties about the agent. Science 279, 42-43
57. 57 Manuelidis L, Sklaviadis T, Akowitz A and Fritch W (1995). Viral particles are required for infection in neurodegenerative Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 92, 5124-5128
58. 58 Gonnerman WA, Kandel R and Cathcart ES (1996). Amyloid enhancing factor is produced by rats and amyloid-resistant CE/J mice. Lab Invest 74, 259-264
59. 59 Elliott-Bryant R and Cathcart ES (1998). Amyloid enhancing factor and dietary transmission in accelerated AA-amyloidosis. Clin Immunol Immunopathol 88, 65-69
60. 60 Neiwold TA, Hol PR, van Andei AC, Lutz ETG and Gruys E. (1987). Enhancement of amyloid induction by amyloid fragments in hamster. Lab Invest 56, 544-49
61. 61 Gadjusek DC (1994). Spontaneous generation of infectious nucleating amyloids in transmissible and non-transmissible cerebral amyloidoses. Mol Neurobiol 8, 1-13
62. 62 Johan K, Westermark G, Engstrom U, Gustavsson A, Hultman P and Westermark P (1998). Acceleration of amyloid A protein amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 95, 2558-2563
63. 63 Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennant GA, Walport MJ and Pepys MB (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 8, 855-859
64. 64 Elliott-Bryant E and Cathcart ES (1997). Apolipoprotein E and apolipoprotein A-a knockout mice readily develop amyloid A protein amyloidosis. Clin Immunol Immunopathol 85, 104-108
65. 65 Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner, M and Cohen AS (1982). Further characterization of amyloid-enhancing factor. Lab Invest 47, 139-146
66. 66 Kedar J, Bleiberg I and Sohar E (1975). Stimulation of murine amyloidosis by a dialyzable product from pre-treated donors. Br J Exp Pathol 70, 579-588
67. 67 Shtrasburg S, Livneh A, Gal R and Pras M (1996). Extremely active murine amyloid enhancing factor. Clin Exp Rheumatol 14, 37-42
68. 68 Yokota T, Takahashi M, Ishihara T, Yamashita Y, Gondo T, Kawamura S, Hoshii Y, Koga M, Iwata T and Uchino F (1991). Amyloid enhancing factor (AEF). Isolation and biochemical and pathological characteristics. Acta Pathol Jpn 41, 798-805
69. 69 Picken MM, Gallo GR and Frangione B (1990). Amyloid enhancing factor (AEF)-induced amyloidosis lacks inflammatory reaction. In Amyloid and amyloidosis. Eds. Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K and Westermark P. Kluwer Academic Publishers. Dordrecht. PP 292-295, 1990
70. 70 Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C and Mucke L (1997). Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease. Nature 389, 603-606
71. 71 Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG and Szarek WA (1996). Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1, 143-148
72. 72 Calkins E and Cohen AS (1960). Diagnosis of amyloidosis. Bull Rheumat Dis 10, 215-218
73. 73 Jenkinson ML, Bliss MR, Brain AT and Scott DL (1989). Rheumatoid arthritis and senile dementia of the Alzheimer's type. Brit J Rheumatol 26, 86-88
74. 74 Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C and Brandt J (1995). Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55
75. 75 Andersen K, Launer LJ, Hoes AW, Breteler MMB and Hofman A (1995). Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 45, 1441-1445